Seelos Therapeutics, Inc.

With Spravato (esketamine) showing signs of solid growth during its fifth year on the market in 2024, Johnson & Johnson got another sign of confidence for the treatment-resistant depression drug o

Kronos Bio Inc. left most of its employees with little to be thankful for on 27 November when it announced a day before the Thanksgiving holiday in the US that in addition to CEO Norbert Bischofberger

The saga of the ALS treatment Relyvrio may be generating ripple effects across the disease landscape. Alon Ben-Noon, CEO of NeuroSense Therapeutics Ltd. , which is developing PrimeC as an amyotrophic

Shortly after a Phase III trial failed to confirm Amylyx Pharmaceuticals, Inc. ’s Relyvrio benefit in amyotrophic lateral sclerosis (ALS), Seelos Therapeutics, Inc. has revealed that its investigat